Logo Image
Feature|Videos|May 18, 2026

CDMO Innovations in Integrated Services

Key Takeaways

  • Understand how Piramal leads the CDMO market in delivering well-constructed and well-executed integrated services.
  • Learn why programs need to consider both drug substance and drug product from the earliest development through commercialization.
SHOW MORE

Discover how Piramal Pharma Solutions is innovating in integrated CDMO services, leveraging their Science Collective of experts to streamline drug substance and drug product programs from early development through commercialization.

Sponsored by Piramal Pharma Solutions

In this video, Jean-François Carniaux, a vice president and global API technical lead at Piramal Pharma Solutions, discusses how the company is advancing its CDMO landscape through integrated service delivery. Operating across approximately 15 sites in India, Europe, and North America, Piramal provides a global infrastructure supporting multiple modalities from early development through commercial supply.

Carniaux elaborates on the importance of aligning drug substance and drug product programs early in the development lifecycle. Piramal’s integrated model enables efficient transitions from API development into drug product manufacturing, supported by coordinated project management and cross-functional technical expertise. This approach helps maintain continuity as programs progress across development phases and global sites.

Carniaux also highlights Piramal’s capabilities in antibody-drug conjugates (ADCs), including its ADCelerator platform, which is designed to streamline development from early-stage work through fill-finish with accelerated timelines. Supporting these efforts, the company has invested approximately $400 million to expand its capabilities in bioconjugation, high-potency API (HPAPI) manufacturing, and sterile fill-finish services.

Related Content